Antidiabetic Activity ofRuellia tuberosaL., Role ofα-Amylase Inhibitor:In Silico,In Vitro, andIn VivoApproaches

Wulan, Dyah Ratna; Utomo, Edi Priyo; Mahdi, Chanif

doi:10.1155/2015/349261

Cited by 22 publications

(7 citation statements)

References 19 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2015) have shown functions of RTL on inhibiting the activity of α‐amylase, delaying carbohydrate decomposition, and reducing postprandial blood glucose disproportion in diabetes. Various phytochemicals of RTL components were reported, including betulin, vanillic acid, flavonoids, apigenin, luteolin, or flavone glycoside (Lin, Huang, Cheng, Sheu, & Chen, 2006; Nair & Subramanian, 1974; Wagner, Danninger, Iyengar, Seligmann, & Farkas, 1971), among which betulin has a major role, act as noncompetitive inhibitors of α‐amylase to achieve hypoglycemia (Wulan et al., 2015). However, isolating and identifying the active components from RTL extracts through column chromatography, high‐performance liquid chromatography, and confirming their benefit functions are currently on the way in our laboratory.…”

Section: Discussionmentioning

confidence: 99%

“…RTL can also regulate the blood glucose and lipid balance in alloxan‐induced diabetic rats and rabbits (Ananthakrishnan & Doss, 2010, 2013; Rajan, Kishor Kumar, Satheesh Kumar, Swathi, & Haritha, 2012; Shahwara et al., 2011; Wulan, Utomo, & Mahdi, 2015). However, there has been no reported literature regarding the effect of RTL on blood glucose homeostasis in T2DM.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ameliorative effect of Ruellia tuberosa L. on hyperglycemia in type 2 diabetes mellitus and glucose uptake in mouse C2C12 myoblasts

Lin

Zeng

et al. 2018

Food Science & Nutrition

View full text Add to dashboard Cite

Ruellia tuberosa L. (RTL) exhibits a wide range of phytochemical activities, for example, on treatment of diabetes mellitus (DM), in Orient. There is, however, few study regarding the effect of RTL on glycemic‐related homeostasis in type 2 DM (T2DM). We investigated the effect of RTL aqueous and ethanolic extracts on hypoglycemia in high‐fat diet (HFD)‐fed plus streptozotocin (STZ)‐induced T2DM rats, and examined the effect of RTL on glucose uptake in tumor necrosis factor‐α‐induced insulin‐resistant mouse C2C12 myoblasts, a mouse skeletal muscle cell line. The administration of 100 or 400 mg kg BW−1 day−1 of RTL aqueous or ethanolic extracts once a day for 4 weeks significantly ameliorated hyperglycemia, hyperinsulinemia, and the insulin resistance (IR) index in diabetic rats. RTL either aqueous or ethanolic extract at a concentration of 25–800 μg/ml significantly improved glucose uptake in insulin‐resistant mouse C2C12 myoblasts, indicating inhibiting the IR in skeletal muscles. These evidences suggest that RTL ameliorates hyperglycemia in HFD/STZ‐induced T2DM rats may be attributed to the alleviation of IR in skeletal muscles.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Ameliorative effect of Ruellia tuberosa L. on hyperglycemia in type 2 diabetes mellitus and glucose uptake in mouse C2C12 myoblasts

Lin

Zeng

et al. 2018

Food Science & Nutrition

View full text Add to dashboard Cite

show abstract

“…Ruellia tuberosa L. is a tradition herbs that possess antioxidant, anticancer, antimicrobial, anti‐inflammatory, antinociceptive, gastroprotective [ 197 ] and antidiabetic activity. [ 198 ] The effect of R. tuberosa L. aqueous (100 mg/kg) and ethanolic (400 mg/kg) extracts on glycaemic control was investigated in diabetic and high‐fat diet rats. [ 199 ] After 4 weeks of treatment, it was found that R. tuberosa L. could ameliorate insulin resistance index, hyperinsulinemia and hyperglycaemia.…”

Section: The Application Of C2c12 Cells In Pharmaceutical Developmentmentioning

confidence: 99%

C2C12 cell model: its role in understanding of insulin resistance at the molecular level and pharmaceutical development at the preclinical stage

Wong

Al‐Salami

Dass

2020

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives The myoblast cell line, C2C12, has been utilised extensively in vitro as an examination model in understanding metabolic disease progression. Although it is indispensable in both preclinical and pharmaceutical research, a comprehensive review of its use in the investigation of insulin resistance progression and pharmaceutical development is not available. Key findings C2C12 is a well-documented model, which can facilitate our understanding in glucose metabolism, insulin signalling mechanism, insulin resistance, oxidative stress, reactive oxygen species and glucose transporters at cellular and molecular levels. With the aid of the C2C12 model, recent studies revealed that insulin resistance has close relationship with various metabolic diseases in terms of disease progression, pathogenesis and therapeutic management. A holistic, safe and effective disease management is highly of interest. Therefore, significant efforts have been paid to explore novel drug compounds and natural herbs that can elicit therapeutic effects in the targeted sites at both cellular (e.g. mitochondria, glucose transporter) and molecular level (e.g. genes, signalling pathway). Summary The use of C2C12 myoblast cell line is meaningful in pharmaceutical and biomedical research due to their expression of GLUT-4 and other features that are representative to human skeletal muscle cells. With the use of the C2C12 cell model, the impact of drug delivery systems (nanoparticles and quantum dots) on skeletal muscle, as well as the relationship between exercise, pancreatic b-cells and endothelial cells, was discovered. Applications and role of C2C12 skeletal muscle Chun Y. Wong et al.

show abstract

“…while n-hexane fraction of methanolic extract of Ruellia tuberose showed that it inhibited (p < .01) α-amylase activity in vivo (Ratna Wulan et al, 2015). Garciniaschom burgkiana bark ethanolic extracts exhibited significant α-amylase and α-glucosidase inhibitory activities with IC 50 value of 20.04 ± 1.33 µg /ml, 2.81 ± 0.43 µg /ml, respectively (Gonsap & Vongsak, 2019).…”

Section: Body Weight (G) Day 28mentioning

confidence: 93%

Improvement in serum amylase and glucose levels in diabetic rats on oral administration of bisdemethoxycurcumin from Curcuma longa and limonoids from Azadirachta indica

2021

View full text Add to dashboard Cite

Curcuma longa and Azadirachta indica are traditionally used in Indian cuisine and Ayurvedic medicine as nutraceuticals against diabetes. The crude C. longa isopropanol extract, bisdemethoxycurcumin (BDMC), the purified bioactive component from C. longa, and limonoids azadiradione, gedunin from A. indica, are able to inhibit in vitro the antidiabetic target human pancreatic α-amylase independently. However, no reports on their in vivo efficacy in animal models exist. Thus, the antidiabetic effect of these orally administered human pancreatic α-amylase inhibitors was performed on streptozotocin-induced Sprague-Dawley rats. Initially, the normal rats were treated with test compounds (10-100 mg/kg of body weight) in corn oil (5 ml/ kg), and as no lethality was observed in these doses, further studies were carried out with lowest concentration of 10 mg/kg of body weight. A reduction in area under curve (AUC) suggested glucose-lowering effect of these compounds in starch fed diabetic rats.The efficacy study showed a significant improvement in body weight, blood glucose levels, serum amylase, and fructosamine levels as well in other serum parameters associated with diabetes with respect to liver and renal functions. Hence, under in vivo conditions, inhibition of α-amylase activity by BDMC and limonoids affirms it as one of the mechanisms of action resulting in reduction of blood glucose levels. Practical applicationsBisdemethoxycurcumin from C. longa and limonoids, namely, azadiradione and gedunin, from A. indica are potent inhibitors of the antidiabetic target human pancreatic α-amylase. Oral Starch Tolerance Test (OSTT) and 28-day efficacy study to check the effect of these orally administered inhibitors in diabetic rat models showed significant improvements in serum blood glucose and amylase levels as well as in other diabetes related serum parameters, namely, bilirubin, lipids, lactate dehydrogenase, alkaline phosphatase, and urea. The study contributes to understanding the action and efficacy of these pancreatic α-amylase inhibitors and suggests a potential role for them as nutraceuticals/therapeutics in management of post-prandial hyperglycemia. How to cite this article: Ramkumar S, Thulasiram HV, RaviKumar A. Improvement in serum amylase and glucose levels in diabetic rats on oral administration of bisdemethoxycurcumin from Curcuma longa and limonoids from Azadirachta indica.

show abstract

Antidiabetic Activity ofRuellia tuberosaL., Role ofα-Amylase Inhibitor:In Silico,In Vitro, andIn VivoApproaches

Cited by 22 publications

References 19 publications

Ameliorative effect of Ruellia tuberosa L. on hyperglycemia in type 2 diabetes mellitus and glucose uptake in mouse C2C12 myoblasts

Ameliorative effect of Ruellia tuberosa L. on hyperglycemia in type 2 diabetes mellitus and glucose uptake in mouse C2C12 myoblasts

C2C12 cell model: its role in understanding of insulin resistance at the molecular level and pharmaceutical development at the preclinical stage

Improvement in serum amylase and glucose levels in diabetic rats on oral administration of bisdemethoxycurcumin from Curcuma longa and limonoids from Azadirachta indica

Contact Info

Product

Resources

About